ADC Therapeutics SA (ADCT) Stock Price Reaches $2.22: What Factors Are Influencing This Level?
Stephens has recently initiated ADC Therapeutics SA (ADCT) stock to Overweight rating, as announced on November 8, 2024, according to Finviz. Earlier, on May 30, 2024, Cantor Fitzgerald had initiated the stock to Overweight. Guggenheim also initiated Buy rating with a price target of $11. Additionally, JP Morgan raised Neutral rating on August 10, 2023. […]
Why Adc Therapeutics SA (NYSE:ADCT) Stock Slipped -12.07% in Last Month?
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
initiated: Cantor Fitzgerald Recommends Adc Therapeutics SA (NYSE:ADCT) Stock to “an Overweight”
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The growth of Adc Therapeutics SA (ADCT) Stock is expected to continue
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
Is it possible to sustain this rally? Adc Therapeutics SA (ADCT) Stock
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The performance of Adc Therapeutics SA (ADCT) Stock has improved
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
What makes Adc Therapeutics SA (ADCT) Stock unique?
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
There Is Nothing Like Adc Therapeutics SA (ADCT) Stock
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]
The latest Adc Therapeutics SA (ADCT) Stock Technical Bulletin
Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]